Active, not recruitingPhase 2NCT05831176

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

Studying Eosinophilic gastroenteritis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Regeneron Pharmaceuticals
Principal Investigator
Clinical Trial Management
Regeneron Pharmaceuticals
Intervention
Dupilumab(drug)
Enrollment
22 enrolled
Eligibility
12 years · All sexes
Timeline
20232026

Study locations (30)

Collaborators

Sanofi

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05831176 on ClinicalTrials.gov

Other trials for Eosinophilic gastroenteritis

Additional recruiting or active studies for the same condition.

See all trials for Eosinophilic gastroenteritis

← Back to all trials